Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis
Sanyal AJ, Newsome PN, Kliers I, et al. New England Journal of Medicine 2025;392:2089-2099.
What it found
In the first 800 participants with biopsy-confirmed MASH and moderate or advanced fibrosis, liver inflammation resolved without worsening scarring in 62.9% vs 34.3% on placebo, and scarring improved without worsening inflammation in 36.8% vs 22.4%. Mean weight change was -10.5% vs -2.0%.
Limitations
Interim results based on liver biopsy findings; whether this leads to fewer cases of cirrhosis, liver failure or death is still being studied in the ongoing part of the trial.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.